Related Experiment Video
Updated: May 5, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
[Heart failure in Germany: epidemiology and recent developments]
Josefine Rudolph1, Stephan von Haehling1,2
1Klinik für Kardiologie und Pneumologie, Universitätsmedizin Göttingen, Göttingen.
Insights
Heart failure management in Germany involves four key drug classes, but these treatments can cause electrolyte imbalances like hypo- or hyperkalemia and iron deficiency. Vigilant monitoring for these complications is crucial for patient safety.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Heart failure with reduced ejection fraction (HFrEF) is a leading cause of hospitalization in Germany, imposing significant burdens.
- Current evidence-based HFrEF management since 2021 relies on four pharmacological pillars: beta-blockers, sacubitril/valsartan (or ACE inhibitors), mineralocorticoid-receptor antagonists, and SGLT-2 inhibitors.
- These essential therapies, while improving outcomes, are associated with adverse effects, particularly electrolyte disturbances and iron deficiency.
Purpose of the Study:
- To review recent epidemiological data on heart failure in Germany and Europe.
- To outline current guideline-directed medical therapies for HFrEF.
- To highlight critical treatment-related complications requiring clinical management.
Main Methods:
- Literature review of recent epidemiological data for heart failure.
- Summary of current guideline-directed therapies for HFrEF.
- Identification and discussion of key treatment-related complications.
Main Results:
- Heart failure remains a primary cause of hospitalization, necessitating careful management.
- The four pillars of HFrEF therapy can lead to hypo- or hyperkalemia, increasing arrhythmia risk.
- Iron deficiency is common in HFrEF patients, with intravenous iron preparations being tested for correction.
Conclusions:
- Effective HFrEF management requires balancing therapeutic benefits with potential adverse effects.
- Vigilant monitoring for electrolyte disturbances (hypo-/hyperkalemia) and iron deficiency is essential.
- Clinicians must be prepared to anticipate and manage these treatment-related complications.
Abstract:
Heart failure is the leading single cause of hospitalisation in Germany and places a heavy clinical and psychosocial burden on patients, families, and caregivers. Since 2021, evidence‑based management of heart failure with reduced ejection fraction (HFrEF) has centred on four pharmacological "pillars": β‑blockers, sacubitril/valsartan (or an ACE inhibitor), mineralocorticoid‑receptor antagonists, and sodium-glucose co‑transporter‑2 (SGLT‑2) inhibitors. While these agents improve survival and quality of life, they also predispose to adverse effects - most notably electrolyte disturbances. Hypo‑ or hyperkalaemia can precipitate malignant arrhythmias and therefore demands vigilant monitoring. Iron deficiency is equally prevalent in the heart‑failure population; randomised trials have primarily tested intravenous iron(III)‑carboxymaltose and iron(III)‑derisomaltose to correct this deficit. This review summarises the most recent epidemiological data for heart failure in Germany and Europe, outlines current guideline‑directed therapies, and highlights key treatment‑related complications clinicians must anticipate and manage.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management

